ArticleDrug design, development and therapy2022

Liquiritin Protects Against Cardiac Fibrosis After Myocardial Infarction by Inhibiting CCL5 Expression and the NF-κB Signaling Pathway.

Xue Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.